- Home
- OVLY vs SLS Comparison
OVLY vs SLS Comparison
Compare OVLY & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OVLY | SLS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 706.7M |
| IPO Year | 2008 | 2007 |
Fundamental Metrics
Financial Performance| Metric | OVLY | SLS |
|---|---|---|
| Price | $32.90 | $5.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 15.7K | ★ 5.5M |
| Earning Date | 04-27-2026 | 04-16-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 62.69 |
| EPS | ★ 2.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.70 | $0.95 |
| 52 Week High | $34.16 | $5.66 |
Technical Indicators
Market Signals| Indicator | OVLY | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.19 | 68.22 |
| Support Level | $32.81 | $1.48 |
| Resistance Level | $34.08 | N/A |
| Average True Range (ATR) | 0.71 | 0.51 |
| MACD | -0.13 | 0.12 |
| Stochastic Oscillator | 51.55 | 83.62 |
Price Performance
Historical ComparisonAbout OVLY Oak Valley Bancorp (CA)
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.